ERBB2 and neoplasm: Therefore, HER2 could serve as an ideal target for antitumor therapy by using CAR-T cells, and a series of preclinical studies applied HER2-specific CAR-T cells to treat gastric cancer9–11.However, CAR-T cells may lead “on target, off tumor” by targeting HER-2-positive normal tissues and cause fatal toxicity12.